Invited Lectures & Special Lectures
Where Did my Mab Go?, AAPS National Biotechnology Meeting, June 2007, San Diego, California
Monoclonal Antibody Pharmacokinetics, Pfizer, June 2007, Groton, Connecticut
PK/PD Considerations for the Optimization of Immunotoxicotherapy, Pfizer, June 2007, Groton, Connecticut
PD Models Relevant to Monoclonal Antibodies, May 2007, Genentech, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, San Francisco, California
Target-Mediated Disposition of Antibodies, May 2007, Genentech, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, San Francisco, California
Dynamics of Bimolecular Interactions: Considerations for Immunotoxicotherapy, May 2007, Genentech, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, San Francisco, California
Pharmacokinetics of Peptides and Proteins, May 2007, Genentech, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, San Francisco, California
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2007, University at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Monoclonal Antibody Pharmacokinetics, New York Academy of Sciences, Symposium on The Future of Monoclonal Antibody Biotherapeutics Production and Development, May 2007, New York, New York
Alphabet Soup: ITP, IVIG, FcRn, & Mab PK, May 2007, University of Kentucky, Lexington, Kentucky
Mechanistic Insights into the ADME Properties of Antibodies and Other Biologics, Merck, March 2007, West Point, Pennsylvania
Target-Mediated Disposition and Dynamics of Biologics: Principles and Applications, Merck, March 2007, West Point, Pennsylvania
Pharmacokinetics and Pharmacodynamics of Antibodies: Work Underway in the Balthasar Laboratory, Amgen, November 2006, Thousand Oaks, California
Monoclonal Antibody Pharmacodynamics, F.Hoffmann-La Roche Ltd, November 2006, Basel, Switzerland
Monoclonal Antibody Pharmacokinetics, F.Hoffmann-La Roche Ltd, November 2006, Basel, Switzerland
Physiologically-based Modeling: General Considerations and Examples, Novartis Pharma AG, October 2006, Basel, Switzerland
Investigations of the influence of FcRn on IgG tissue and systemic disposition, Novartis Pharma AG, October 2006, Basel, Switzerland
Use of Simulation to Guide the Selection of Optimal Monoclonal Antibodies for Immunotoxicotherapy, Novartis Pharma AG, October 2006, Basel, Switzerland
Pharmacokinetic / Pharmacodynamic Modeling and Immunotoxicotherapy, Novartis Pharma AG, October 2006, Basel, Switzerland
Target-Mediated Monoclonal Antibody Disposition, Novartis Pharma AG, October 2006, Basel, Switzerland
Monoclonal Antibody Pharmacokinetics & Pharmacodynamics, Novartis Pharma AG, October 2006, Basel, Switzerland
Monoclonal Antibodies: Pharmacokinetic & Pharmacodynamic Modeling, Cognigen, September 2006, Amherst, New York
Distribution, Clearance, and PK/PD Modeling: Special Considerations for Proteins and Peptides, Merck, June 2006, North Wales, Pennsylvania.
Mab PK Overview, AAPS Workshop on Current Trends in Monoclonal Antibody Development and Manufacturing, AAPS National Biotechnology Meeting, June 2006, Boston, Massachusetts.
Application of FcRn Inhibitors for the Treatment of Humoral Autoimmune Diseases, AAPS National Biotechnology Meeting, June 2006, Boston, Massachusetts.
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2006, University at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Antibody Pharmacokinetics and Pharmacodynamics: Focus on Issues Relevant for Immunotoxicotherapies, May 2006, Wyeth, Collegeville, Pennsylvania.
PK/PD Correlations of Monoclonal Antibodies, April 2006, 5th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijkerhout, The Netherlands.
Antibody Pharmacokinetics, April 2006, Pfizer, Ann Arbor, Michigan.
FcRn Inhibition: An Important Mechanism for IVIG Effects in ITP? March 2006, Department of Oral Biology, University at Buffalo, The State University of New York, Buffalo, New York.
Pharmacokinetic Strategies to Optimize IP Chemotherapy for Ovarian Cancer, January 2006, Rutgers University, New Brunswick, New Jersey.
Studies assessing the effects of an anti-FcRn antibody on the disposition of anti-platelet antibodies and on anti-platelet antibody-induced thrombocytopenia in a mouse model of sustained ITP, December 2005, ITP Study Group Meeting (in conjunction with the Annual Meeting of the American Society of Hematology), Atlanta, Georgia.
Comparison of anti-RBC immunotherapy, IVIG, and antibody-cated liposome therapies in a mouse model of sustained ITP, December 2005, ITP Study Group Meeting (in conjunction with the Annual Meeting of the American Society of Hematology), Atlanta, Georgia.
Antibody Pharmacokinetics and Pharmacodynamics: Are there important differences relative to small molecule PK/PD?, November 2005, Schering Plough Research Institute, Kenilworth, New Jersey.
FcRn-inhibition: An important mechanism for IVIG effects in immune thromobocytopenia? September 2005, University of Minnesota, Minneapolis, Minnesota
Development of FcRn inhibitors for autoimmunity, August 2005, Genentech, San Francisco, California.
Antibody Pharmacokinetics and Pharmacodynamics, June 2005, Wyeth, Boston, Massachusetts.
Application of pharmacokinetic / pharmacodynamic modeling to expedite the discovery and development of monoclonal antibodies for immunotoxicotherapy, June 2005, National Biotechnology Conference of the American Association of Pharmaceutical Scientists, San Francisco, California
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2005, University at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Pharmacokinetic Strategies to Optimize IP Chemotherapy, February 2005, Pharmacology and Therapeutics Department, Grace Cancer Drug Center, Roswell Park Memorial Cancer Institute, Buffalo, New York.
Pharmacokinetics and Pharmacodynamics of Antibodies, January 2005, International Symposium for Life Sciences and Medicine, Keio University, Tokyo, Japan. (Pictures)
Mechanisms and Kinetics of IgG Elimination, November 2004, Sunrise School, Annual Meeting of the American Association of Pharmaceutical Scientists, Baltimore, MD
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2004, University at Buffalo – Leiden/Amsterdam Center for Drug Research Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Inverse Targeting for Optimization of Intraperitoneal Chemotherapy, May 2004, Department of BiopharmaceuticalSciences, University of Illinois, Chicago, Illinois
Inverse Targeting with Anti-Drug Antibodies, April 2004, University of Kentucky, Division of Pharmaceutical Sciences, College of Pharmacy, Lexington, Kentucky
Pharmacodynamic Analyses for Assessment of Equivalence of Biotech Products, November 2003, Expert Panel on Complex Activities, United States Pharmacopoeia, Rockville, Maryland
Competitive Inhibition of FcRn: An important mechanism of IVIG action?, November 2003, Annual Meeting of the American Association of Blood Banks, San Diego, California
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2003, University at Buffalo – Leiden/Amsterdam Center for Drug Research Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Application of PK/PD to Investigate Mechanisms of IVIG Action in ITP, May 2003, Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Role of FcRn in IgG Metabolism: Implications for Therapeutic Antibodies and Autoimmunity, January 2003, Molecular Biopharmaceutics Meeting, Waikiki, Hawaii
Antibody PK/PD: New Insights & Applications, November 2002, Buffalo Pharmaceutics Symposium, University at Buffalo, The State University of New York, Amherst, New York
Evidence for a New Mechanism of IVIG Action, October 2002, The University of Michigan, Department of Pharmaceutical Sciences, College of Pharmacy, Ann Arbor, Michigan
Bioreactor Accelerated Immunotoxicotherapy, August 2002, Industrial Science & Technology Network Inc., York, Pennsylvania
Investigation of IVIG Mechanism of Action in ITP: Application of new findings to identify targets for therapy, June 2002, The University of Michigan, Yang Laboratory, Department of Pharmaceutical Sciences, College of Pharmacy, Ann Arbor, Michigan
Application of Kinetic – Dynamic Modeling to Predict Antibody Effects in an Inverse Targeting Strategy, May 2002, University of North Carolina, Division of Drug Delivery and Disposition, College of Pharmacy, Chapel Hill, North Carolina
Case Study: Application of PK/PD Modeling to Delineate Mechanisms of IVIG Action in Immune Thrombocytopenia, May 2002, Georgetown University Center for Drug Development Science: Workshop on ‘Physiologically Based Pharmacokinetics in Drug Development and Regulatory Science’, Washington, DC
Monoclonal Antibodies, May 2002, University at Buffalo – Leiden/Amsterdam Center for Drug Research Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
New Insights Into the Mechanism of IVIG Action in Immune Thrombocytopenia, April 2002, University of Kentucky, Division of Pharmaceutical Sciences, College of Pharmacy, Lexington, Kentucky
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, May 2001, University at Buffalo – Leiden/Amsterdam Center for Drug Research Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Pharmacokinetics and Pharmacodynamics of Antibodies, May 2000, University at Buffalo – Leiden/Amsterdam Center for Drug Research Pharmacokinetic – Pharmacodynamic Concepts and Applications Course, Buffalo, New York
Pharmacology and Bioengineering of New Treatments for Immune Thrombocytopenia, January 2000, The University of Michigan, Yang Laboratory, Department of Pharmaceutics, College of Pharmacy, Ann Arbor, Michigan
Animal Models of Immune Thrombocytopenia: Application for the Development and Evaluation of New Treatments for ITP, January 2000, University at Buffalo, Department of Pharmaceutics, Buffalo, New York
Inverse Targeting: New Approaches of Enhancing the Selectivity of Ovarian Cancer Chemotherapy, August 1999, University at Buffalo, Department of Pharmaceutics, Buffalo, New York
Inverse Targeting: A New Approach for Enhancing the Selectivity of the Chemotherapy of Peritoneal Tumors, July 1999, Huntsman Cancer Institute, Salt Lake City, Utah
Understanding the Influence of Drug Formulation on PK/PD: Introduction of a New Inverse-Targeting Approach, May 1999, Lipocine Inc., Salt Lake City, Utah
Optimization of Cancer Chemotherapy, February 1999, Utah State University, Department of Chemistry, Logan, Utah
Optimization of intraperitoneal cancer chemotherapy with anti-drug antibodies: Pharmacokinetic rationale and experimental results, November 1995, American Association of Pharmaceutical Scientists, Eli Lilly Graduate Symposium, Miami, Florida